StockData
HCW Biologics Inc. logo

HCW Biologics Inc. (HCWB) stock

HCWBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3095% below fair value
$0.76−0.01 (-1.65%)

Close on Nov 18, 2026Market cap $1.40MP/E –Yield –

HCW Biologics gross margin

Gross margin is gross profit as a percentage of revenue.

HCW Biologics's gross margin for the twelve months ending Jun 30, 2026 was 96.7%. For fiscal 2025 it was 20.0%, against 37.4% the year before.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202520.0%−17.4
FY2024Dec 31, 202437.4%+17.7
FY2023Dec 31, 202319.7%−18.8
FY2022Dec 31, 202238.5%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-77.1%−97.1
Q1 FY2026Mar 31, 2026100.5%+80.5
Q4 FY2025Dec 31, 202520.0%−0.0
Q3 FY2025Sep 30, 202520.0%−0.0
Q2 FY2025Jun 30, 202520.0%−9.2
Q1 FY2025Mar 31, 202520.0%−34.6
Q4 FY2024Dec 31, 202420.0%+0.9
Q3 FY2024Sep 30, 202420.0%−0.5
Q2 FY2024Jun 30, 202429.2%+9.8
Q1 FY2024Mar 31, 202454.6%+24.6
Q4 FY2023Dec 31, 202319.1%−0.9
Q3 FY2023Sep 30, 202320.5%+0.5
Q2 FY2023Jun 30, 202319.3%−17.4
Q1 FY2023Mar 31, 202329.9%−27.5
Q4 FY2022Dec 31, 202220.0%–
Q3 FY2022Sep 30, 202220.0%–
Q2 FY2022Jun 30, 202236.7%–
Q1 FY2022Mar 31, 202257.4%–

More HCW Biologics figures

See a number that looks wrong?